Alex KoyfmanPosted December 1, 2016
While it's hard for the average person on the street to see the use in buying shares of a company and never liquidating, there are some infinite-term investments that just about every one of us...
Monica SavagliaPosted November 30, 2016
Emblem, a fully integrated medical marijuana, health care, and cannabinoid-based pharmaceutical company, is on the verge of making its market debut on the TSX-V.
Briton RylePosted November 30, 2016
Well, well. It looks like the brain trust at OPEC may have finally hammered out an arrangement to lower its price-crushing oil production levels. All I can say is: it's about time.
Jeff SiegelPosted November 29, 2016
With the end of a brutal dictatorship, will Cuba finally embrace the spoils of capitalism? With Fidel Castro out of the picture, a new road to liberty may soon be possible for the people of Cuba.
Briton RylePosted November 28, 2016
Is that it? Is it just "game over" for brick-and-mortar retail stores? Well, if you go by Back Friday numbers, then yeah, traditional retail is down for the count.
Jason StutmanPosted November 27, 2016
Wealth Daily editor Jason Stutman shares his picks for the best and worst stocks of the 2017 Christmas season.
Briton RylePosted November 23, 2016
Before the election, the consensus was that Trump would tank the markets and possibly send the U.S. into recession. Now, the jury's still out on how the economy will perform, but the stock market...
Jeff SiegelPosted November 22, 2016
Are Amazon and Alibaba too big to destroy? One company, OpenBazaar, is attempting to do just that. But it isn't the tech stock you should be looking for...
Jason StutmanPosted November 20, 2016
Google, SpaceX, and others are disrupting major ISPs with a new kind of Internet. These are the winning and losing stocks.
Jeff SiegelPosted November 18, 2016
Jim Chanos is bearish on the fracking industry. You should be, too.
Monica SavagliaPosted November 18, 2016
CRISPR Therapeutics (NASDAQ: CRSP) experienced a lackluster initial public offering in October, but things are looking up. They've announced that their gene-editing technology was used for the first...
Jason WilliamsPosted November 18, 2016
With stocks on a tear, fixed income investments are getting the cold shoulder. But yields are so high that investors can't ignore these bonds much longer. It's time to lock in some risk-free yields.